Member Societies

• All
• Nov. 13 (Thu)
• Nov. 14 (Fri)
• Nov. 15 (Sat)

• KSG
• KSGE
• KASL
• KSNM
• KPBA
• KCHUGR
• KASID
• KSGC
• KSPGHAN
• Editor Session

Symposium 01: Distinguished papers of 2024–2025 in Clinical and Molecular Hepatology English

Date / Time	Nov. 13 (Thu), 09:00-10:35
Room	Vista 1
Chair(s)	Yoon Jun Kim (Seoul National University, Korea) Hyung Joon Kim (Chung-Ang University, Korea)
Speakers	09:00-09:15	The CMH journey: Global growth and author guidance Yeonjung Ha (CHA University, Korea)
	09:15-09:35	CMH clinical research highlight–Dynamic analysis of acute deterioration in chronic liver disease patients using modified quick sequential organ failure assessment Do Seon Song (The Catholic University of Korea, Korea)
	09:35-09:55	CMH clinical trial highlight–Antiviral therapy for chronic hepatitis B with mildly elevated aminotransferase: A rollover study from the TORCH-B trial Yao-Chun Hsu (I-Shou University, Taiwan)
	09:55-10:15	CMH epidemiologic research highlight–Extrahepatic malignancies and antiviral drugs for chronic hepatitis B: A nationwide cohort study Jeong-Hoon Lee (Seoul National University, Korea)
	10:15-10:35	CMH multinational research highlight–Carvedilol to prevent hepatic decompensation of cirrhosis in patients with clinically significant portal hypertension stratified by new non-invasive model (CHESS2306) Xiaolong Qi (Southeast University, China)

Presidential Lecture: Chung Yong Kim memorial lecture Korean

Date / Time	Nov. 13 (Thu), 10:50-11:20
Room	Vista 1
Chair(s)	Sook-Hyang Jeong (Seoul National University, Korea)
Speakers	10:50-11:20	The liver odyssey: Four decades of progression and hope Joong-Won Park (Myongji Hospital, Korea)

Free Paper 03: Liver 01 English

Date / Time	Nov. 13 (Thu), 10:50-11:30
Room	Grand 4+5
Chair(s)	Won Hyeok Choe (Konkuk University, Korea) Byungseok Lee (Chungnam National University, Korea)
Speakers	10:50-11:00	Shear wave elastography combined with ALBI score enhances prediction of hepatic decompensation in cirrhosis Jaejun Lee (The Catholic University of Korea, Korea)
	11:00-11:10	Hepatic encephalopathy and prognosis in cirrhosis with acute decompensation: Influence of liver function and coagulation Jung Hee Kim (Hallym University, Korea)
	11:10-11:20	Scheuer G-S asynchrony in liver cirrhosis: A three-metabolite signature predicts discordant fibrosis-inflammation trajectories and guides precision anti-fibrotic therapy Zijian Zhang (The First Affiliated Hospital of Sun Yat-sen University, China)
	11:20-11:30	Comparative evaluation of MELD, MELD-Na, MELD-LA, and MELD-DELTA in predicting mortality in critically ill cirrhotic patients: A prospective study Vikas Reddy (Dr Knruhs, India)

Free Paper 04: Liver 02 English

Date / Time	Nov. 13 (Thu), 11:30-12:20
Room	Grand 4+5
Chair(s)	Suk Bae Kim (Dankook University, Korea) Sungjae Park (Inje University, Korea)
Speakers	11:30-11:40	Unraveling the role of per- and polyfluoroalkyl substances (PFAS) in oxidative stress-mediated progression of non-alcoholic fatty liver disease Hina Parveen (King George Medical University, India)
	11:40-11:50	Emerging indices outperform traditional fibrosis scores in young MASLD across divergent screening goals Ahlim Lee (The Catholic University of Korea, Korea)
	11:50-12:00	Non-invasive prediction of major adverse liver outcomes using the acNASH model: Evidence from a nationwide cohort and single-center validation Yeo Wool Kang (Dong-A University, Korea)
	12:00-12:10	PNPLA3 I148M is not associated with HCC risk but correlates with tumor differentiation in MASLD patients Dong Yeup Lee (The Catholic University of Korea, Korea)

Symposium 09: Special considerations for liver diseases in distinct conditions English

Date / Time	Nov. 13 (Thu), 13:20-14:50
Room	Vista 1
Chair(s)	Young-Suk Lim (University of Ulsan, Korea) Ji Hoon Kim (Korea University, Korea)
Speakers	13:20-13:42	Risk-stratified prophylaxis for HBV reactivation in patients receiving biological agents Pin-Nan Cheng (National Cheng Kung University, Taiwan)
	13:42-14:04	Management of anti-HBc or HBsAg-positive donors and recipients in liver transplantation Deok Gie Kim (Yonsei University, Korea)
	14:04-14:26	Risks and benefits of statins and DOACs in cirrhotic patients with cardiovascular disease Ho Soo Chun (Ewha Womans University, Korea)
	14:26-14:48	Current controversies in HCC risk and surveillance after SVR in HCV-infected patients Ryosuke Tateishi (The University of Tokyo, Japan)
	14:48-14:50	Q&A

Free Paper 09: Liver 03 English

Date / Time	Nov. 13 (Thu), 13:20-14:00
Room	Grand 4+5
Chair(s)	Gab Jin Cheon (University of Ulsan, Korea) Tae Hee Lee (Konyang University, Korea)
Speakers	13:20-13:30	Serum HBV markers reflect intrahepatic cccDNA and transcriptional activity in a phase-dependent manner in chronic HBV infection Hye Seon Kim (The Catholic University of Korea, Korea)
	13:30-13:40	Global mortality burden and health inequalities of hepatitis virus-related liver cancer and forecast to 2050 Yujiao Deng (The Second Affiliated Hospital of Xi’an Jiaotong University, China)
	13:40-13:50	Safety of Tenofovir alafenamide in the context of hyperlipidemia and cardiovascular diseases: A nationwide analysis Jae-Young Kim (Soonchunhyang University, Korea)
	13:50-14:00	Cost-effectiveness of screening for hepatitis C virus infection among people who inject drugs in South Korea Hye-Lin Kim (Sahmyook University, Korea)

Free Paper 10: Liver 04 English

Date / Time	Nov. 13 (Thu), 14:00-14:50
Room	Grand 4+5
Chair(s)	Dae Won Jun (Hanyang University, Korea) Jeong Heo (Pusan National University, Korea)
Speakers	14:00-14:10	Development of a machine learning-based model for predicting survival in hepatocellular carcinoma patients undergoing transarterial chemoembolization as initial treatment Yeo Wool Kang (Dong-A University, Korea)
	14:10-14:20	LI-RADS imaging diagnosis facilitates assessment of liver transplant eligibility in HCC: Analysis of 1,008 patients Yeongseok Hwang (University of Ulsan, Korea)
	14:20-14:30	Global mortality and disability-adjusted life years burden of population with liver cancer and diabetes: During 2005–2021 and forecast to 2035 Yujiao Deng (The Second Affiliated Hospital of Xi’an Jiaotong University, China)
	14:30-14:40	Real-life experience of systemic treatment with Regorafenib in patients with hepatocellular carcinoma: Updated analysis through 2025 Hee Sun Cho (The Catholic University of Korea, Korea)
	14:40-14:50	Development and validation of a risk prediction model for patients with hepatocellular carcinoma receiving atezolizumab-bevacizumab Heechul Nam (The Catholic University of Korea, Korea)

Symposium 13: Big data in hepatology research: Sources and applications English

Date / Time	Nov. 13 (Thu), 15:10-16:40
Room	Vista 1
Chair(s)	Si Hyun Bae (The Catholic University of Korea, Korea) Sang Hoon Ahn (Yonsei University, Korea)
Speakers	15:10-15:32	Korean nationwide population-based study using the National Health Information Database Han Ah Lee (Chung-Ang University, Korea)
	15:32-15:54	Taiwanese nationwide database for chronic viral hepatitis Mei-Hsuan Lee (National Yang Ming Chiao Tung University, Taiwan)
	15:54-16:16	Common data models for real-world data analysis Rae Woong Park (Ajou University, Korea)
	16:16-16:38	Hepatocellular carcinoma in the setting of alcohol-related liver disease: insights from French prospective cohort studies Pierre Nahon (Université Sorbonne Paris Nord, France)
	16:38-16:40	Q&A

Symposium 17: Optimizing treatment strategies for HCC: Concurrent and sequential approaches English

Date / Time	Nov. 14 (Fri), 08:30-10:00
Room	Vista 2
Chair(s)	Han Chu Lee (University of Ulsan, Korea) Jae Young Jang (Soonchunhyang University, Korea)
Speakers	08:30-08:52	The priority decision for subsequent systemic therapy after first-line failure of ICI-based regimens for HCC Arndt Vogel (University of Toronto, Canada)
	08:52-09:14	Promising systemic agents for combination therapy with TACE and their mechanistic rationales in incurable HCC Sung Won Chung (University of Ulsan, Korea)
	09:14-09:36	Role of radiotherapy for advanced-stage HCC in the era of IO Jeong Il Yu (Sungkyunkwan University, Korea)
	09:36-09:58	Efficacy and safety of ICI-based treatment for Child-Pugh B HCC Jean-Charles Nault (Université Sorbonne Paris Nord, France)
	09:58-10:00	Q&A

Symposium 22: In vitro and in vivo experimental models to study liver diseases Korean

Date / Time	Nov. 14 (Fri), 10:20-11:50
Room	Vista 2
Chair(s)	Jung-Hwan Yoon (Seoul National University, Korea) Won-Il Jeong (KAIST, Korea)
Speakers	10:20-10:50	Models for hepatitis B and the associated liver cancers Kyun-Hwan Kim (Sungkyunkwan University, Korea)
	10:50-11:20	Preclinical MASH studies Sang Geon Kim (Dongguk University, Korea)
	11:20-11:50	Cancer immunotherapy research Tae-Jin Kim (Korea Institute of Radiological & Medical Sciences, Korea)

Symposium 27: Biomarkers for diagnosis, treatment response, and prognosis in liver diseases English

Date / Time	Nov. 14 (Fri), 13:20-14:50
Room	Vista 2
Chair(s)	Jia-Horng Kao (National Taiwan University, Taiwan) Moon Seok Choi (Sungkyunkwan University, Korea)
Speakers	13:20-13:42	Early predictors of hepatitis B relapse after antiviral cessation Cheng-Hao Tseng (I-Shou University, Taiwan)
	13:42-14:04	Biomarkers for monitoring disease progression in MASLD Nobuharu Tamaki (Musashino Red Cross Hospital, Japan)
	14:04-14:26	Imaging markers predicting response to IO in HCC Subin Heo (University of Ulsan, Korea)
	14:26-14:48	Histological markers for differential diagnosis of liver tumors and inflammatory conditions Haeryoung Kim (Seoul National University, Korea)
	14:48-14:50	Q&A

PG Course 04: Guidelines and evidence-based recommendations in liver disease management Korean

Date / Time	Nov. 14 (Fri), 15:10-16:40
Room	Grand 1
Chair(s)	Neung Hwa Park (University of Ulsan, Korea) Sungbum Cho (Chonnam National University, Korea)
Speakers	15:10-15:32	Chronic hepatitis B: Antiviral strategy Won-Mook Choi (University of Ulsan, Korea)
	15:32-15:54	Chronic hepatitis C: Antiviral strategy Young Kul Jung (Korea University, Korea)
	15:54-16:16	MASLD: Current and potential new treatments Won Sohn (Sungkyunkwan University, Korea)
	16:16-16:38	Liver cirrhosis: Complications and specific management Do Seon Song (The Catholic University of Korea, Korea)
	16:38-16:40	Q&A

USG: Abdominal US training specialist 01 Korean

Date / Time	Nov. 15 (Sat), 08:30-10:00
Room	Walker 1
Chair(s)	Moon Young Kim (Yonsei University Wonju, Korea)
Speakers	08:30-08:52	Experiences and challenges in ultrasound education Tae Suk Kim (Kangwon National University, Korea)
	08:52-09:14	Clinical practice guidelines for the managing pancreatic cystic neoplasm Yoonseok Lee (Gachon University, Korea)
	09:14-09:36	CEUS LI-RADS for diagnosis of hepatocellular carcinoma Jae Seok Bae (Seoul National University, Korea)
	09:36-09:58	Recent advances and future perspectives in spleen stiffness measurement Jeong-Ju Yoo (Soonchunhyang University, Korea)
	09:58-10:00	Q&A

USG: Abdominal US training beginner Korean

Date / Time	Nov. 15 (Sat), 08:30-10:00
Room	Walker 2
Chair(s)	Ki Tae Suk (Hallym University, Korea)
Speakers	08:30-09:00	Scanning technique for the beginner: Liver Ji Won Park (Hallym University, Korea)
	09:00-09:30	Scanning technique for the beginner: Pancreato-biliary Heechul Nam (The Catholic University of Korea, Korea)
	09:30-10:00	Clinical approach for common abdominal US findings: Cystic liver disease & GB polyp Ji Eun Han (Ajou University, Korea)

USG: Abdominal US training specialist 02 Korean

Date / Time	Nov. 15 (Sat), 10:20-11:50
Room	Walker 1
Chair(s)	Sang Gyune Kim (Soonchunhyang University, Korea)
Speakers	10:20-10:42	Noninvasive assessment of hepatic steatosis in MASLD era Tae Seop Lim (Yonsei University, Korea)
	10:42-11:04	Advancements and future directions in elastography for portal hypertension Young Chang (Soonchunhyang University, Korea)
	11:04-11:26	US guided percutaneous biopsy of abdominal viscera Jeong Woo Kim (Korea University, Korea)
	11:26-11:48	Future of AI and digital solutions in ultrasound Daehyoun Cho (GE Healthcare, Korea)
	11:48-11:50	Q&A